Evidence map›Paper›PMID 32932783›Full record

ArticleMolecules (Basel, Switzerland)2020

Evaluation of a New

Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, Melpomeni Fani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rosalba MansiDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-0342-8865
Guillaume Pierre NicolasDivision of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Luigi Del PozzoDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland.
Karim Alexandre AbidCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of Lausanne, 1011 Lausanne, Switzerland.
Eric GrouzmannCatecholamine and Peptides Laboratory, Department of Laboratories, University Hospital of Lausanne, 1011 Lausanne, Switzerland.
Melpomeni FaniDivision of Radiopharmaceutical Chemistry, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland.
University Hospital of Basel · CHUniversity Hospital of Lausanne · CH

Funding

Kommission für Technologie und Innovation 18282.2 PFLS-LS
6 · The paper itself

Abstract

Targeted radionuclide therapy of somatostatin receptor (SST)-expressing tumors is only partially addressed by the established somatostatin analogs having an affinity for the SST subtype 2 (SST2). Aiming to target a broader spectrum of tumors, we evaluated the bis-iodo-substituted somatostatin analog ST8950 ((4-amino-3-iodo)-d-Phe-c[Cys-(3-iodo)-Tyr-d-Trp-Lys-Val-Cys]-Thr-NH

Indexed as

AnimalsGastrointestinal NeoplasmsHEK293 CellsHumansInhibitory Concentration 50KidneyLutetiumMiceNeoplasm TransplantationOctreotidePeptidesProtein BindingRadioisotopesRadiometryReceptors, SomatostatinSingle Photon Emission Computed Tomography Computed TomographyLutetiumLutetium-177OctreotidePeptidesRadioisotopesReceptors, SomatostatinSomatostatinsomatostatin receptor 5SSTR2 protein, humandual-tumor mouse modelLu-177neuroendocrine tumorsradiolabeled somatostatin analogsSST2SST5targeted radionuclide therapy

Identifiers

PMID32932783
PMCPMC7570871
OpenAlexW3084849385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.